Medical Oncology, University Hospitals Birmingham Foundation Trust, Birmingham, UK.
Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Oncology. 2022;100(12):666-673. doi: 10.1159/000526140. Epub 2022 Aug 31.
This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.
Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).
Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).
DISCUSSION/CONCLUSION: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.
本研究对英国 14 家医院转移性乳腺癌（MBC）患者接受艾立布林治疗的真实世界数据进行了评估。
对接受艾立布林治疗的 MBC 患者进行回顾性匿名数据收集。数据包括激素受体状态、组织学诊断、年龄、既往化疗、艾立布林治疗反应、无进展生存期（PFS）和总生存期（OS）。
在分析的 577 例患者中，中位年龄为 56 岁，大多数患者（73%）为雌激素受体阳性。中位 OS 为 288 天（95%CI：261-315），中位 PFS 为 117 天（95%CI：105-129）。老年患者（≥65 岁与<65 岁：325 天[95%CI：264-385]与 285 天[95%CI：252-317]；p=0.028）中位 OS 更高。接受艾立布林治疗前化疗线数较少（≤2 线与>2 线：328 天[95%CI：264-385]与 264 天[95%CI：229-298]；p=0.042）的患者中位 OS 也更高。
讨论/结论：这些回顾性数据表明，艾立布林可成功用于老年 MBC 患者。早期治疗线中艾立布林治疗更有效，虽然可以预见，但支持将艾立布林考虑作为二线治疗选择。
